** Shares of Genscript Biotech Corporation slip 2.7% to HK$11.32, their lowest since February 2021
** Stock on course for a third straight session of declines
** Genscript Biotech says unit Legend Biotech announced that cancer cell therapy Carvykti generated $157 mln in net trade sales during the quarter ended March 2024
** Johnson & Johnson reports Q1 sales of Legend-partnered Carvykti of $157 mln, below an estimated $200.50 mln sales by at least two analysts
** Carvykti has recently received approval for use in less-severely affected patients with a type of blood cancer
** U.S.-listed shares of Legend Biotech fell 3.1% on Tuesday
** Hong Kong's healthcare index slips 0.5%, Hang Seng Composite Index eases 0.1% and Hang Seng Index
down 0.2%
** Genscript Biotech stock down 42.3% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Comments